Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours.

Francesco Caiazza  
Royal College of Surgeons in Ireland

Nina S. McCarthy  
Royal College of Surgeons in Ireland

Leonie Young  
Royal College of Surgeons in Ireland

Arnold DK Hill  
Royal College of Surgeons in Ireland

Brian J. Harvey  
Royal College of Surgeons in Ireland

See next page for additional authors

Citation
Full Paper

Cytosolic phospholipase A2-α expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours

F Caiazza1, NS McCarthy1, L Young2, ADK Hill2, BJ Harvey1 and W Thomas*1

1Department of Molecular Medicine, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland; 2Department of Surgery, Royal College of Surgeons in Ireland, Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland

BACKGROUND: The eicosanoid signalling pathway promotes the progression of malignancies through the production of proliferative prostaglandins (PGs). Cytosolic phospholipase A2-α (cPLA2-α) activity provides the substrate for cyclooxygenase-dependent PG release, and we have previously found that cPLA2-α expression correlated with EGFR/HER2 over-expression in a small number of breast cancer cell lines.

METHODS: The importance of differential cPLA2-α activity in clinical breast cancer was established by relating the expression of cPLA2-α in tissue samples from breast cancer patients, and two microarray-based gene expression datasets to different clinicopathological and therapeutic parameters.

RESULTS: High cPLA2-α mRNA expression correlated with clinical parameters of poor prognosis, which are characteristic of highly invasive tumours of the HER2-positive and basal-like subtype, including low oestrogen receptor expression and high EGFR expression. High cPLA2-α expression decreased overall survival in patients with luminal cancers, and correlated with a reduced effect of tamoxifen treatment. The cPLA2-α expression was an independent predictive parameter of poor response to endocrine therapy in the first 5 years of follow-up.

CONCLUSION: This study shows a role of cPLA2-α in luminal breast cancer progression, in which the enzyme could represent a novel therapeutic target and a predictive marker.

British Journal of Cancer (2010) 0, 000–000. doi:10.1038/sj.bjc.6606025 www.bjcancer.com

© 2010 Cancer Research UK

Keywords: phospholipase; EGFR; breast cancer; oestrogen

Breast cancer is the most common malignancy diagnosed in women and the leading cause of cancer-related death in women worldwide, accounting for ~500 000 deaths per year and representing 15% of all female cancer-related mortality (Hortobagyi et al, 2005). Early detection and improved treatment account for the decline in mortality rates that has been observed in the past two decades (Jemal et al, 2007). Molecular characterisation and profiling has improved our understanding of the heterogeneity of breast cancer, and is now an important clinical tool to predict the course of the disease and identify the most appropriate treatment regimen for each patient (Perou et al, 2000; Sorlie et al, 2001; Hu et al, 2006).

Accordingly, oestrogen receptor (ER)-positive patients are treated with adjuvant endocrine therapy (such as tamoxifen or fulvestrant; Jordan, 2007), and HER2-positive patients can benefit from targeted therapy. Moreover, patients with ER-negative, progesterone receptor (PR)-negative and HER2-negative tumours (triple-negative, or basal-like cancers) lack an established therapeutic target and can only be treated with conventional chemotherapy (Linn and Van’t Veer, 2009). It is, therefore, crucial to improve the translational effort in order to identify molecular markers that could aid in the prediction of tumour progression, prognosis and therapeutic regimen.

The group IVA cytosolic phospholipase A2 (cPLA2-α) is an enzyme that catalyses the hydrolysis of the sn-2 linkage in membrane glycerol- phospholipids to release arachidonic acid (AA), which is then converted to biologically active eicosanoid lipid mediators, including prostaglandin E2 (PGE2), produced by cyclooxygenase (COX)-2 (Leslie, 1997). The PGE2 has important regulatory roles in diverse cellular responses, including cell growth and differentiation; accordingly, the AA-based eicosanoid signalling pathway has been implicated in the development and progression of cancer in different human tissues, including the breast (Nakanishi and Rosenberg, 2006; Thomas et al, 2008).

Clinical, epidemiological and molecular evidence has linked COX-2 expression/activation and PGE2 production to breast cancer progression (reviewed in Howe, 2007). We have previously reported that cPLA2-α expression/activation and PGE2 production to breast cancer progression (reviewed in Howe, 2007). We have previously reported that cPLA2-α can be rapidly activated by physiological concentrations of 17β-estradiol (E2) and is involved in the proliferative effects of E2 in breast cancer cell (Thomas et al, 2006, 2008; Caiazza et al, 2010). Specifically, the E2-induced
activation of cPLA₂ is mediated by trans-activation of EGFR/HER2 heterodimers signalling through ERK1/2 mitogen-activated protein kinase (Caiazzza et al., 2010), resulting in the activation of proliferative signals in both ER-positive and ER-negative breast cancer cells. Pre-clinical data support a role for EGFR/HER2 signalling in promoting E2-independent tumour growth and in the development of resistance to endocrine therapy (Knowleden et al, 2003). In agreement with these data, clinical evidence shows that over-expression of both EGFR and HER2, which is found in 50 and 30% of breast cancer, respectively, correlates with a decreased sensitivity to endocrine therapy and with poor patient prognosis (Pietras, 2003). Furthermore, over-expression of HER2 receptors and related signalling is a molecular determinant of selective loss of ER expression, progression to ER-negative invasive phenotype and development of resistance to selective ER modulators-based therapy (Lopez-Tarruella and Schiff, 2007). Consequently, in the past 20 years, HER2 has become an important prognostic marker and therapeutic target in breast cancer. Taking into account the involvement of EGFR/HER2 receptors in the E2-induced activation of cPLA₂ in breast cancer cell lines, it was hypothesised that cPLA₂ activity and expression could be correlated with HER2-overexpressing tumours, a suggestion that is also supported by previous studies showing a correlation between expression of intermediates in the eicosanoid signalling pathway, particularly COX-2, and HER2 over-expression in breast cancer (Vadalami et al, 1999; Ristimaki et al, 2002; Subbaramaiah et al, 2002; Wulfing et al, 2003). We previously reported a novel correlation between cPLA₂ and HER2 over-expression in a small number of cell lines (Caiazzza et al, 2010). This study investigates the relationship between cPLA₂ and EGFR/HER2 in vivo, addressing the clinical implications of differential cPLA₂ expression in breast cancer.

PATIENTS AND METHODS

Patient samples and quantitative real-time PCR (qRT–PCR)

Ethical approval and patient consent was obtained for access to primary tumour samples from 18 breast cancer patients who underwent surgery at Beaumont Hospital (Dublin, Ireland) between 2008 and 2009. In all, 15 patients were ER positive and 3 were ER negative as determined by standard histopathological evaluation. The patients had not been treated with adjuvant endocrine therapy; however, the majority had received selective oestrogen receptor modulator therapy with tamoxifen. The patients had not been treated with adjuvant chemotherapy; however, the majority had received selective oestrogen receptor modulator therapy with tamoxifen. The patients had not been treated with adjuvant endocrine therapy; however, the majority had received selective oestrogen receptor modulator therapy with tamoxifen. The patients had not been treated with adjuvant endocrine therapy; however, the majority had received selective oestrogen receptor modulator therapy with tamoxifen.

RNA extraction and qRT–PCR were performed as previously described (Caiazzza et al, 2010). Expression levels of HER2 mRNA were normalised to a standard housekeeping gene (18S rRNA) and calibrated to the MCF-7 cell line chosen to represent 1 × expression of HER2 gene (Barberis et al, 2008) All samples above a threshold of HER2 mRNA expression relative to the calibrator were assigned to the HER2-positive group. This method was previously validated by comparing HER2 mRNA levels in 55 formalin-fixed, paraffin-embedded samples, in which HER2 status was evaluated by IHC and fluorescence in situ hybridisation (Barberis et al, 2008).

Gene expression microarrays

The expression of PLA2G4A (probe 210145_at), EGFR (probe 210984_s_at) and ERBB2 (probe 210930_s_at) was examined in two previously published microarray data sets of breast cancer cell lines (Kao et al, 2009) and primary tumour samples (van de Vijver et al, 2002), which had been profiled with an Affymetrix microarray platform (Affymetrix). Data were downloaded, respectively, from the PLOS website (http://dx.plos.org/10.1371/journal.pone.0006146) and from the original publication on-line supporting information website (http://microarray-pubs.stanford.edu/wound_NKI/explore.html). Comprehensive clinical data of all 295 patients were also available from the same source.

Statistical analysis

Statistical analysis of the data were performed with paired Student’s t-test for analysis between two groups. Fisher’s exact test was performed on contingency tables to analyse the correlation between two variables. Pearson’s coefficient was used to measure correlation between linear variables. Survival curves were calculated according to the Kaplan–Meier method and compared using the Cox–Mantel log-rank test. Overall survival (OS) was calculated as the time between the first date of treatment and the last date of follow-up or the date of death. Relapse-free survival (RFS) was calculated as the time between the first date of treatment and the last date of follow-up or date of recurrence (loco-regional recurrence or distant metastasis). Kaplan–Meier curves were calculated, as indicated, over the entire follow-up time (17 years) or over a follow-up time of 10 years to focus on the effects on early development of acquired endocrine resistance. All analysis were performed using prism (Graphpad software). Cox proportional hazard models were computed using XLStat-Life for Microsoft Excel (Kovach Computing Services). The cPLA₂ expression was categorised as high or low using the upper median as a cutoff point. Where indicated, the median was used as a cutoff point to exclude any possible bias because of the low number of patients. All other variables were either dichotomised or analysed as continuous variables as indicated. The number of patients in each group is reported in the figure legend. Heat-map image was generated from microarray data using the Matrix2png web interface (University of British Columbia, http://chibi.ubc.ca/ matrix2png; Pavlidis and Noble, 2003). All P-values are two-tailed, and P-values of <0.05 were considered statistically significant.

RESULTS

Increased expression of cPLA₂ mRNA correlates with HER2 over-expression in breast cancer patients

The expression of cPLA₂ was analysed by qRT–PCR in tumour samples from a cohort of Irish breast cancer patients (complete clinical data for the 18 patients are detailed in Supplementary Table S1). Recently, the validity of IHC to test for HER2 amplification has been questioned in terms of standardisation, reproducibility and accuracy (Gown, 2008), and different groups have reported results supporting a better accuracy of qRT–PCR in detecting HER2 amplification, avoiding false positives and false negatives (Vinatzer et al, 2005; Kulka et al, 2006). Consequently, we quantified HER2 expression in all 18 samples using qRT–PCR. In all, 9 samples out of 18 (50%) scored as HER2 positive using the described method, including some that were previously classified as HER2 negative using standard pathological evaluation. Expression of cPLA₂ mRNA was significantly (P<0.01) increased in HER2-positive tissue samples (Figure 1).

Increased expression of cPLA₂ mRNA correlates with the basal-like and HER2-positive subtypes, and with markers of poor prognosis in a panel of breast cancer cell lines

With the aim of expanding our study to a larger sample size population, we first analysed the expression of cPLA₂ in a panel of 30 breast cancer cell lines for which gene expression microarray data were previously published (Kao et al, 2009). Increased expression of cPLA₂ correlated with high expression of EGFR
and with low expression of ERα at the mRNA level (Figure 2A). No significant correlation was found between cPLA₂-γ and HER2 expression, but this was influenced by missing data for HER2 mRNA expression levels. High cPLA₂-γ abundance clustered in cell lines characterised by basal phenotype compared with luminal phenotype, and cPLA₂γ expression also correlated with basal-like and HER2-positive subtypes as opposed to luminal A and luminal B subtypes (Figure 2B). High EGFR expression, low ERα, the basal and HER2-positive subtypes are all molecular markers of poor prognosis in breast cancer. High cPLA₂-γ expression also correlated with two different profile signatures that are predictive of poor prognosis: the 70 gene (van ’t Veer et al, 2002) and the wound response (Chang et al, 2005) signatures (Figure 2B).

**Figure 1** Expression of cPLA₂-γ mRNA according to HER2 expression in breast cancer tissue samples. Samples from 18 breast cancer patients were separated into HER2-positive and HER2-negative groups according to qRT-PCR quantification and threshold of HER2 expression, as indicated in Materials and methods. Expression of cPLA₂-γ mRNA, measured by qRT-PCR, was compared amongst the two groups. **P<0.01 measured by Student’s t-test.

Increased expression of cPLA₂-γ mRNA correlates with clinical parameters of poor prognosis in a cohort of breast cancer patients

Expression of cPLA₂-γ was investigated in a second gene expression microarray dataset comprising 295 breast cancer patients from The Netherland Cancer Institute (van de Vijver et al, 2002). There was a positive correlation between cPLA₂-γ and EGFR mRNA expression (Pearson R² = 0.056, \( P<0.0001 \)), but no correlation between cPLA₂-γ and HER2 expression (\( P=0.7816 \)). High cPLA₂-γ mRNA abundance correlated with ER-negative status as opposed to ER positive (\( P<0.0001 \)), and with basal phenotype compared with luminal (\( P<0.0001 \); Figure 3A and B and Supplementary Table S2). When compared with the TNM staging system, high cPLA₂-γ expression correlated with size of the primary tumour (T) of >2 cm (\( P<0.05 \); Figure 3C) but not with lymph node involvement (N) or with distant metastasis (M). Increased cPLA₂-γ abundance also correlated with histology grade 3 tumours compared with grade 1 and 2 (\( P<0.05 \)) and with the activated wound response model (a gene signature predictive of poor prognosis (Chang et al, 2005)) (\( P<0.001 \)). Correlation with the 70 gene profile signature almost reached statistical significance (\( P=0.0528 \); Figure 3D–F and Supplementary Table S2). In spite of the correlation between high cPLA₂-γ mRNA expression and different clinical parameters characteristic of poor prognosis, cPLA₂-γ itself was not associated with poor prognosis in both univariate and multivariate analysis (Figure 4 and Supplementary Table S3). Patients with high cPLA₂-γ expression had a reduced 7 years OS compared with patients expressing low cPLA₂-γ, but this was not statistically significant (\( P=0.1 \); Figure 4A). However, when the same analysis was repeated separately on luminal and basal tumour patient data, high cPLA₂-γ expression was associated with reduced OS in patients with luminal cancer (\( P<0.01 \); Figure 4B and C).

**Figure 2** Correlation between cPLA₂-γ mRNA expression and clinico-pathological characteristics in a panel of 30 breast cancer cell lines. (A) Log2 expression levels of cPLA₂-γ (PLA2G4A), ERα (ESR1), EGFR and HER2 (ERBB2) are depicted by the indicated pseudo-colour scale (grey represents missing or poorly measured data). (B) Classification of cell lines by ER status, by positivity for 70 gene and wound response signatures, and by nearest resemblance to tumour gene expression subtype (normal, luminal A, luminal B, HER2 positive, basal-like).

Increased expression of cPLA₂-γ correlates with poor response to endocrine therapy in breast cancer patients

Increased expression of EGFR/HER2 and decreased expression of ERα are molecular markers associated with resistance to endocrine therapy in breast cancer (Pietras, 2003). We investigated the relationship between cPLA₂-γ expression and the development of endocrine resistance in The Netherland Cancer Institute cohort.
of 295 breast cancer patients (see Supplementary Table S4 for subset sizes). Although patients who expressed cPLA₂α most highly, had a reduced RFS when treated with endocrine therapy compared with patients who received no adjuvant hormonal treatment, according to Kaplan–Meier univariate survival analysis, these data did not reach statistical significance ($P = 0.56$ and...
intracellular arachidonic acid availability; this in turn would have a dual effect on tumour cells by reducing proliferative PGE2 production and also block the supply of arachidonic acid to alternate pathways, such as those mediated by COX-1 and lipoxygenase. This alternate metabolism of arachidonic acid represents a serious negative side effect that was reported with the clinical use of COX-2-specific inhibitors, which may be over come through specific cPLA2 antagonism (Laye and Gill, 2003). We previously demonstrated that selective pharmacological inhibition of cPLA2 leads to the growth inhibition of breast cancer cells in vitro (Caiazza et al, 2010). It is, therefore, crucial to determine whether cPLA2 has any value as a putative therapeutic target in vivo, and also to investigate which specific subset of breast cancer patients may benefit the most from such intervention. We previously found through in vitro studies that there was a correlation between high cPLA2 expression and HER2 over-expression at both mRNA and protein level in a small panel of breast cancer cell lines (Caiazza et al, 2010), this expression correlation may be explained by a bi-directional cross-talk between the two proteins; in whom HER2 can regulate the expression of cPLA2 that in turn function by modulating the transcription of HER2 through the production of PGE2 (Benoit et al, 2004; Caiazza et al, 2010). A similar synergy was also reported between HER2 and COX-2 expression (Benoit et al, 2004; Wang et al, 2006; Thomas et al, 2008). Antagonism of cPLA2 would limit free


discussion

The role of eicosanoid signalling in carcinogenesis has been the subject of intense investigation over the past 20 years, particularly in the context of COX-2 over-expression. The dysregulation of cPLA2, through alterations in its functional activity or in expression levels, is also a common feature of many types of human cancer including mammary adenocarcinoma, leading to high levels of proliferative eicosanoids (Nakanishi and Rosenberg, 2006; Thomas et al, 2008). Antagonism of cPLA2 would limit free

Table 1

<table>
<thead>
<tr>
<th>Variable</th>
<th>Hazard ratio (95% CI)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low cPLA2 (vs high)</td>
<td>0.244 (0.069 – 0.862)</td>
<td>0.028</td>
</tr>
<tr>
<td>Hormonal therapy (vs no hormonal therapy)</td>
<td>0.384 (0.172 – 0.855)</td>
<td>0.019</td>
</tr>
</tbody>
</table>

Abbreviations: CI = confidence interval, cPLA2 = cytosolic phospholipase A2; ER = oestrogen receptor; aCI (adjusted for ER and HER2 status). Total patients = 124 (hormonal = 20, no hormonal = 104, PLA2 high = 4, PLA2 low = 120).

Figure 5

Role of cPLA2 in the early development of endocrine resistance in 295 breast cancer patients. Kaplan–Meier analysis of the probability that patients would remain free of distant metastases (A) among patients treated only with radiotherapy/chemotherapy and patients treated with adjuvant tamoxifen therapy, according to cPLA2 expression (high, n = 31 vs low, n = 224 for radio/chemotherapy and high, n = 5 vs low, n = 35 for adjuvant therapy), total follow-up time of 17 years; (B) among all patients or patients with high cPLA2 expression, according to the presence or absence of adjuvant endocrine therapy (non-endocrine, n = 203 vs endocrine, n = 38 for all patients; non-endocrine, n = 94 vs endocrine, n = 17 for cPLA2 positive patients), follow-up time of 10 years; (A and B) Survival curves were compared using the Cox–Mantel log-rank test. The corresponding \( \chi^2 \) values and P-values are indicated. The threshold for cPLA2 dichotomisation in (B) was lowered to the median in order to include more patients; the statistical significance was retained as compared with the analysis with the median cutoff point (not shown), suggesting the absence of bias because of the low number of patients.
et al, 2004), and as a consequence COX-2 over-expression is associated with HER2-driven tumourigenesis in vivo (Howe et al, 2005; Dillon et al, 2008). In this study, we report a correlation between cPLA2 and high HER2 mRNA expression in a group of 18 breast cancer patients. This was subsequently confirmed by the analysis of a gene expression microarray of 30 breast cancer cell lines, in which high mRNA expression of cPLA2 correlated with high EGFR expression and with the HER2-positive and basal-like subtypes of breast cancer in cell lines showing basal phenotype. The molecular classification of breast cancer, based on the seminal subtypes of breast cancer in cell lines showing basal phenotype.

The work of Perou and colleagues in the seminal study (Perou et al, 2000) identified five main subtypes of tumours with distinct patterns of gene expression and different disease outcomes: luminal A and luminal B cancers (mainly ER positive and sensitive to endocrine therapy), HER2 positive (ER negative or with low ER expression, HER2 over-expressing and resistant to endocrine therapy), basal-like (ER negative, PR negative and HER2 negative, also called triple negative) and normal-like. In our in silico analysis of gene expression microarrays from both cell lines and patients, elevated cPLA2 mRNA expression was associated with clinical parameters for poor prognosis, which correlate with the HER2-positive and basal-like subtypes of breast cancer. Low ER expression, high EGFR expression, activation of poor prognosis profile signatures, large tumour size and high histological grade all associated significantly with high cPLA2 mRNA expression. So supporting the hypothesis that cPLA2 could represent a specific therapeutic target for a clinically challenging subset of breast cancer patients with highly invasive, endocrine resistant tumours of the HER2-positive or triple-negative subtype. In spite of the association between cPLA2 expression and different clinicopathological parameters characteristic of poor prognosis, cPLA2 was not directly associated with poor prognosis, but only correlated with reduced overall survival in patients with the luminal type of cancer. This result suggested that cPLA2 could predict prognosis specifically in luminal breast cancers, and hence be indicative of the response to endocrine therapy. Over-expression of EGFR/HER2 and downregulation of ER are molecular markers associated with de novo and acquired resistance to endocrine therapy in both pre-clinical models of breast cancer and in clinical studies (Knowlden et al, 2003; Schiff et al, 2005). Several studies have provided indirect evidence of a role for the eicosanoid signalling pathway in the development of endocrine resistance, including the PGE2-mediated, enhanced expression of HER2 (Benoit et al, 2004) and expression of aromatase (Zhao et al, 1996). Direct evidence also supports a role for COX-2 as an independent prognostic marker for poor response to tamoxifen treatment in breast cancer patients (Dillon et al, 2008). In this study, we analysed cPLA2 expression with regards to hormonal treatment in a population of 295 breast cancer patients that were either treated with adjuvant tamoxifen (alone or in combination with chemotherapy) or did not receive any adjuvant endocrine treatment. High cPLA2 mRNA was measured in only a small subset of the patients who received endocrine therapy, and increased cPLA2 expression in this group predicted poor response to endocrine therapy in the first 5 years of follow-up in univariate analysis. The cPLA2 was also an independent prognostic marker of poor response to endocrine therapy in a multivariate analysis that also included hormonal treatment, ER and HER2 expression to adjust for any bias because of the association of cPLA2 expression with ER negativity (which itself correlates with endocrine resistance). This analysis only takes into account treatment with tamoxifen and does not include other types of endocrine therapies, such as aromatase inhibition.

In summary, the data presented in this work provide evidence of a role for cPLA2 in breast cancer progression; cPLA2 expression correlated with clinicopathological parameters of poor prognosis and with highly aggressive tumours characterised by low ER expression, high EGFR expression and basal phenotype. This work also provides evidence to support a role for cPLA2 as a predictive marker for poor prognosis, and suggest a role in the early onset of resistance to tamoxifen therapy, in luminal cancers; this is in common with what has been previously reported for COX-2 expression (Dillon et al, 2008). Targeting eicosanoid pathway intermediates may prove a valuable strategy to overcome acquired resistance to tamoxifen treatment of breast cancer, and it has been suggested that specific antagonism of cPLA2 could be useful in augmenting treatment (Thomas et al, 2008). In this study, we show that patients with highly aggressive cancers of the HER2-positive and basal-like subtypes, as well as patients with luminal tumours who developed resistance to endocrine therapy, are most likely to benefit from such a therapeutic strategy, due to their higher cPLA2 expression levels.

ACKNOWLEDGEMENTS

We thank Dr Charles Perou and Dr Fan Cheng (University of North Carolina at Chapel Hill, USA) for their assistance with data retrieval. The bioinformatic expertise of Dr Alessandro Montaghini (University of Florence, Italy) is also acknowledged. This work was supported by the Higher Education Authority of Ireland (PRTLI Cycle 4) through the National Bio-Photonics and Imaging Platform, and by a PhD scholarship to FC from The Royal College of Surgeons in Ireland.

Supplementary Information accompanies the paper on British Journal of Cancer website (http://www.nature.com/bjc)

REFERENCES


Received 29th November 2010


Zhao Y, Agarwal VR, Mendelson CR, Simpson ER (1996) Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 137: 5739–5742

© 2010 Cancer Research UK British Journal of Cancer (2010) 00(0), 1–7